Healthcare & Pharmaceuticals

S.Africa's Aspen aims to expand vaccine capacity to 1.3 bln doses a year

1 minute read

An Aspen Pharmacare logo is seen at outside company offices in Woodmead, Johannesburg, South Africa, September 13, 2018. REUTERS/Siphiwe Sibeko/File Photo

GQEBERHA, South Africa, Oct 25 (Reuters) - South Africa's Aspen Pharmacare (APNJ.J) wants to increase vaccine manufacturing capacity at its domestic plant to 1.3 billion doses a year, CEO Stephen Saad told a news conference on Monday.

Aspen, which has a fill and finish deal for Johnson & Johnson's (JNJ.N) COVID-19 vaccine, has said it has capacity to manufacture up to 300 million doses a year of the J&J vaccine. It was not immediately clear from Saad's speech whether he was referring to expanding capacity for COVID-19 vaccines only or all vaccines.

Register now for FREE unlimited access to
Reporting by Promit Mukherjee Writing by Alexander Winning Editing by David Goodman

Our Standards: The Thomson Reuters Trust Principles.

More from Reuters